Pioglitazone
|
| Catalog No.GC14948 |
Pioglitazone (PIO) is a thiazolidinedione antidiabetic drug that acts as a PPARγ agonist. The EC50 of PPARγ in human and mouse was 0.93 and 0.99 µM, respectively..
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 111025-46-8
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Pioglitazone belongs to the class of glitazones or thiazolidinediones, a series of oral anti-diabetic drugs. Pioglitazone is a ligand for peroxisome proliferator-activated receptor γ (PPARγ) that acts as a PPARγ agonist with EC50 of 0.93 and 0.99 µM for human and mouse PPARγ[1-2].
Pioglitazone (10 µM;4h) reversed the decrease in AMPK activity caused by high glucose in INS-1 cells [3]. Pioglitazone (50 µM;48h) also inhibited tumor cell proliferation in the multicellular tumor spheroid culture system (MCTS) system[4].
Pioglitazone (oral,10 or 30 mg/kg once daily for 14 days) improves insulin resistance and diabetes[5].Four weeks of pioglitazone (10 or 20 mg/kg, daily, from 20- to 24-week-old) treatment alleviated the high-fat diet (HFD)-induced glucose-metabolic dysfunctions, upregulation of ventral hippocampal glial fibrillary acidic protein (GFAP), reduction of the total process lengths and the number of branch points of the ventral hippocampal CA1 GFAP-immunoreactive astrocytes and depressive phenotypes in mice[6]. Pioglitazone (oral gavage;10 mg/kg; once daily for 4 weeks) significantly reduced body weight (BW) myocardial hypertrophy glucose levels and improved associated dyslipidemia[7].
References:
[1]. Kuwabara K, Murakami K,et,al. A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice. J Pharmacol Exp Ther. 2004 Jun;309(3):970-7. doi: 10.1124/jpet.103.064659. Epub 2004 Feb 24. PMID: 14982965.
[2]. Legchenko E, Chouvarine P, et,al. PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med. 2018 Apr 25;10(438):eaao0303. doi: 10.1126/scitranslmed.aao0303. PMID: 29695452.
[3]. Karunakaran U, Elumalai S, et,al. Pioglitazone-induced AMPK-Glutaminase-1 prevents high glucose-induced pancreatic β-cell dysfunction by glutathione antioxidant system. Redox Biol. 2021 Sep;45:102029. doi: 10.1016/j.redox.2021.102029. Epub 2021 Jun 3. PMID: 34107382; PMCID: PMC8187239.
[4]. Gottfried E, Rogenhofer S, et,al. Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids. Cancer Chemother Pharmacol. 2011 Jan;67(1):117-26. doi: 10.1007/s00280-010-1294-0. Epub 2010 Mar 9. PMID: 20217088.
[5]. Kubota N, Terauchi Y, et,al. Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem. 2006 Mar 31;281(13):8748-55. doi: 10.1074/jbc.M505649200. Epub 2006 Jan 23. PMID: 16431926.
[6]. Lam YY, Tsai SF, et,al. Pioglitazone rescues high-fat diet-induced depression-like phenotypes and hippocampal astrocytic deficits in mice. Biomed Pharmacother. 2021 Aug;140:111734. doi: 10.1016/j.biopha.2021.111734. Epub 2021 May 19. PMID: 34022606.
[7]. Elrashidy RA, Asker ME, et,al. Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy. J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):324-33. doi: 10.1177/1074248411431581. Epub 2012 Jan 18. PMID: 22261714.
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *